To observe the clinical efficacy and safety of Qinghao Biejia decoction in improving the bone metastasis of lung cancer and to explore its effects on cytokines. Methods:Ninety patients with lung cancer complicated with bone metastasis admitted in our hospital from February 2015 to August 2017 were randomly divided into control group and observation group, with 45 cases in each group. Two groups of patients were treated with paclitaxel and cisplatin chemotherapy. The observation group was added Qinghao Biejia Decoction. The clinical efficacy, the level of cytokines, and clinical benefit of two groups were compared. Results:1) The effective rate was 8622% in the observation group and 6812% in the control group. The difference was statistically significant (P<005), and the observation group was better than the control group. 2) There was no difference in immune function of the two groups of patients before treatment (P<005). The observation group was significantly improved after treatment, and the difference was statistically significant (P<005). 3) The stability and improvement of KPS and body weight in the observation group were significantly higher than those in the control group (P<005), and the difference was statistically significant (P<005). 4) There was no significant difference in the levels of IL-2, IL-6, IL-10 and TNF-α between the two groups before treatment (P>005). After treatment, the above indicators were lower than before treatment, but the observation group decreased more significantly. Conclusion:Qinghao Biejia decoction can significantly improve the immunity and anti-inflammatory level of patients with lung cancer and bone metastasis, and can improve its clinical curative effect.